Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 162 participants.

Also called NCT02347111

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 162 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02347111
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT02347111. Randomized; no masking; primary purpose treatment. Start 2020-12-31 (actual); primary completion 2026-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
Intervention (Drug)
Flecainide
Intervention (Drug)
Sotalol
Lead sponsor
University of Illinois Chicago (class: other)
Collaborator
Medtronic (class: industry)

Record details

Record id
cardio:ct-nct02347111
Content hash
3666de46679f32247e6483e3e60cbc4866e41988a91120f855e3d1d0f7ce7fd0